Arch Therapeutics Inc
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and… Read more
Arch Therapeutics Inc (ARTH) - Total Liabilities
Latest total liabilities as of June 2024: $13.96 Million USD
Based on the latest financial reports, Arch Therapeutics Inc (ARTH) has total liabilities worth $13.96 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arch Therapeutics Inc - Total Liabilities Trend (2013–2023)
This chart illustrates how Arch Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Arch Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Arch Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sage Group PLC
LSE:SGE
|
UK | GBX2.99 Billion |
|
Woodlandor Holdings Bhd
KLSE:7025
|
Malaysia | RM7.74 Million |
|
Minera IRL Limited
PINK:MRLLF
|
USA | $170.77 Million |
|
Seya Industries Limited
NSE:SEYAIND
|
India | ₹7.87 Billion |
|
Exceed World Inc
PINK:EXDW
|
USA | $6.72 Million |
|
Tearlach Resources Ltd
V:TEA
|
Canada | CA$1.02 Million |
|
Insight Acquisition Corp. Class A Common Stock
NASDAQ:INAQ
|
USA | $13.33 Million |
|
Sino AG
XETRA:XTP
|
Germany | €2.06 Million |
Liability Composition Analysis (2013–2023)
This chart breaks down Arch Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arch Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arch Therapeutics Inc (2013–2023)
The table below shows the annual total liabilities of Arch Therapeutics Inc from 2013 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-09-30 | $9.47 Million | +39.28% |
| 2022-09-30 | $6.80 Million | +44.54% |
| 2021-09-30 | $4.70 Million | +28.77% |
| 2020-09-30 | $3.65 Million | -1.56% |
| 2019-09-30 | $3.71 Million | +6.59% |
| 2018-09-30 | $3.48 Million | -9.92% |
| 2017-09-30 | $3.86 Million | +94.81% |
| 2016-09-30 | $1.98 Million | -19.47% |
| 2015-09-30 | $2.46 Million | -68.30% |
| 2014-09-30 | $7.77 Million | +454.83% |
| 2013-09-30 | $1.40 Million | -- |